RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal
RBC Downgrades Alpine Immune Sciences to Sector Perform From Outperform, Removes Speculative Risk, Lifts Price Target to $65 From $41 Amid Vertex Deal
加拿大皇家銀行將阿爾卑斯免疫科學的評級從跑贏大盤下調至板塊，消除投機風險，在頂點交易中將目標股價從41美元上調至65美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊